REVELATION BIOSCIENCES, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Revelation Biosciences reported cash of $11.5M as of June 30, 2026 (up from $10.7M at year-end 2025), funded partly by January 2026 warrant inducement proceeds. Six-month net loss was $6.3M; operating burn for Q2 2026 was $2.6M. Management projects cash sufficient through Q1 2027. Phase 2/3 Gemini trial for acute kidney injury targeting enrollment start by year-end 2026; independent market assessment valued AKI opportunity at $94B.
Why this rating
Routine earnings disclosure for micro-cap ($3.4M market value). Burn rate ($2.6M/quarter) consumes ~76% of quarterly cash; runway through Q1 2027 is near-term and will require financing. Clinical progress is standard; no transformational deal or crisis.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.